12:00 AM
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PRI-724: Phase I/II started

Prism began an open-label, U.S. Phase I/II trial evaluating IV PRI-724 in about 140 patients with advanced myelogenous malignancies. The trial comprises a Phase Ia portion to determine the maximum tolerated dose (MTD) of PRI-724, a Phase Ib expansion portion to further define the safety of the MTD and a Phase...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >